| INTRODUCTION
Oesophageal and gastric cancer are among the most common cancers in the world, with around 456 000 and 952 000 new cases diagnosed annually. 1 Prognosis is extremely poor, even in developed countries such as the United Kingdom, where 55% of patients die within 1 year of diagnosis. 2 Those who survive suffer a marked reduction in their quality of life during treatment and recovery. 3, 4 Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used and effective treatments for hypertension, heart failure and diabetic neuropathy. 5, 6 In England, ARBs are recommended as a first-line pharmacological treatment for hypertension patients aged under 55 or with comorbid diabetes, 7, 8 and nearly 20 million prescriptions are dispensed annually. 9 An estimated 200 million patients are treated with ARBs worldwide, representing 25% of all antihypertensive agents. 10 ARBs reduce blood pressure by blocking angiotensin II type I receptors within the reninangiotensin system, however evidence of local expression of reninangiotensin system components within cancer cells 11, 12 has fuelled debate that they might also affect cancer tumour development. 11, 13 In-vitro and mouse models at various cancer sites have shown that
ARBs reduce tumour growth, stimulate cell apoptosis, reduce metastasis, and inhibit angiogenesis, suggesting that several chemopreventive mechanisms are possible. [14] [15] [16] [17] [18] More specifically, ARBs have been shown to slow proliferation, inhibit fibrosis, and prevent stressinduced injury in gastric cancer cell line and animal model studies. [19] [20] [21] [22] [23] Despite convincing preclinical evidence that ARBs could influence cancer risk and progression, studies in humans are inconsistent.
A meta-analysis of secondary outcomes from randomised controlled trials found little evidence of an association between ARB use and cancer risk, 24 while a meta-analysis of observational studies reported reduced cancer risk among long-term ARB users. 25 Observational studies of cancer progression are fewer, but have found improved outcomes among ARB or angiotensin converting enzyme (ACE) inhibitor (an alternative antihypertensive medication which also inhibits the renin-angiotensin system) users across several cancer sites, while also highlighting methodological issues with the current literature such as poor generalisability, short follow-up, inadequate case-mix adjustment and potential exposure misclassification. 26, 27 To date, no studies have investigated ARB use and gastro-oesophageal mortality, although olmesartan has been shown to cause severe enteropathy in some patients, suggesting upper-gastrointestinal effects. 28 Consequently, we used a large population-based dataset from the UK to robustly assess this association.
2 | ME TH ODS
| Data sources
Our study used data from the English National Cancer Data Reposi- 
| Statistical analysis
We calculated descriptive statistics and compared the demographic, lifestyle and clinical characteristics of the ARB users and non-users.
We produced survival graphs using the Simon-Makuch method, which is an alternative to the Kaplan-Meier but appropriately accounts for time-varying covariates. 36 We used time-dependant
Cox regression models to calculate hazard ratios (HRs) comparing gastro-oesophageal cancer-specific death between ARB users and non-users. We conducted analyses for gastro-oesophageal cancer, and separately for oesophageal (ICD-10 code C15) and gastric (ICD-10 code C16) cancer. In our primary analysis we included ARB use as a time-varying covariate to avoid immortal time bias. 37 Therefore patients were initially included within the analysis as non-users until 6 months after their first use (due to the exposure lag), after which they were included as users until the end of follow-up. Our primary analysis adjusted for age at diagnosis, year of diagnosis (separate term for each year), deprivation quintile, comorbidities (separate terms for each), post-diagnosis use of aspirin or statins (using timevarying covariates and a 6 month lag after their first prescription), cancer site (gastric or oesophageal), and treatment within 6 months of diagnosis (separate terms for surgery, chemotherapy, radiotherapy). We repeated our analysis by number of DDDs prescribed (e.g.
patients were included in the 1-364 DDD group until 6 months after they received their 365th DDD), and for candesartan and losartan, the most commonly prescribed ARBs. 9 Again, the use of time-varying covariates negates immortal time bias. We conducted interaction tests to assess differences by tumour type.
| Sensitivity and subgroup analyses
We conducted sensitivity analysis for all-cause mortality, and for cause-specific mortality where deaths with a secondary cause (i.e.
listed as an "other cause of death" on death certificate) of gastrooesophageal cancer were included. We also conducted sensitivity analyses with a lag period of zero (patients followed up from diagnosis) and 12 months (patients followed up from 12 months after diagnosis). We performed two simplified analyses which controlled for immortal time bias without time-varying covariates. 37 Firstly, we based ARB usage on the 6 months after diagnosis, and followed up patients from 6 months after diagnosis. Secondly, we investigated ARB usage in the year prior to diagnosis, and followed up patients from the date of diagnosis. Diagrams illustrating the design of our sensitivity analyses which vary the exposure lag and/or period are given in Appendix S2. We conducted subgroup analysis by tumour type (i.e. adenocarcinoma and squamous cell carcinoma), as these differ in incidence, risk factors and pathogenesis. We also carried out sub-group analysis restricted to patients receiving surgery, as they are likely to form a more homogenous group of earlier-stage patients.
To assess if confounding by indication was driving our results, we conducted three further sensitivity analyses restricted to patients with similar clinical diagnoses. First, we restricted our analysis to patients with a hypertension diagnosis (Read code categories G20
and 662) in the year prior to cancer diagnosis. Second, we restricted our analysis to patients who received an antihypertensive medication (diuretics, vasodilator antihypertensive drugs, centrally acting antihypertensive drugs, alpha-adrenoceptor blocking drugs, beta-blockers, ACE inhibitors, ARBs, renin inhibitors and calcium channel blockers)
in the year prior to cancer diagnosis. Third, we compared patients who received ARBs to those who received a different antihypertensive medication after diagnosis (using a time-varying covariate), as the use of an active comparison can overcome several common pharmacoepidemiological biases. 38 Similarly, we conducted negative control analyses 39 for ACE inhibitors as they have similar indications to ARBs, but a distinct biological mechanism within the renin-angiotensin system. Therefore, if confounding was driving our ARB BUSBY ET AL.
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analyses we would expect to see similar associations for ACE inhibitors. Conversely, findings of a substantial association for ARBs, which are not replicated among the negative controls, would support a causal interpretation.
We performed additional sensitivity analysis adjusting for tumour prognostic features (stage, grade) and patient lifestyle factors (smoking, alcohol consumption, BMI) using multiple imputation with chained equations. Briefly, this is a simulation-based approach for handling missing data which leads to valid statistical inferences under certain assumptions. 40 The imputation used ordered logit models with age, deprivation, death indicator and the baseline hazard function as covariates. Lastly, we used the Fine and Gray sub-distribution hazard model to assess the impact of competing risks from non gastro-oesophageal cancer deaths. 41 3 | RESULTS
| Cohort description
We identified 9714 gastro-oesophageal cancer cases with no prior cancer diagnosis registered at Clinical Practice Research Datalink practices. We excluded 4590 patients as they had either less than 6 months follow-up (n = 4582) or a duplicate record in the National
Cancer Data Repository (n = 8), leaving 5124 patients for analysis.
Median follow-up was 1.4 years (maximum 17.2 years). ARB users were more likely to be female, have comorbidities (particularly diabetes, renal disease and congestive heart disease), be treated with statins or aspirin after diagnosis, undergo surgery, be non-or exsmokers, and be obese (Table 1) .
| Association between ARB use and survival
Overall, ARB users were at a moderately lower risk of gastro-oesophageal cancer death than non-users both before (unadjusted HR = 0.80, 95% CI 0.69-0.94; Figure 1 ) and after adjustment for demographics, comorbidities, cancer treatments and post-diagnosis aspirin or statin use (adjusted HR = 0.83, 95% CI 0.71-0.98; Table 2 ). There was evidence of a dose-response relationship 
| Sensitivity and subgroup analyses
Our results were similar in the simpler analysis basing ARB use on the year prior, or 6-months after diagnosis (Table 3 ). Our conclusions were unchanged when expanding our cancer-specific death definition to include secondary death causes, and for all-cause mortality.
Our results were robust to alterations in the exposure lag period from 0 to 12 months, and did not change appreciably when adjust- 4 | DISCUSSION
| Summary of main findings
In this large, population-based cohort of newly diagnosed gastrooesophageal cancer patients, we found a statistically significant reduction of 17% in cancer-specific morality among ARB users after adjustment for patient demographics, comorbidities, cancer treatments and post-diagnosis aspirin or statin use. There was some evidence of a dose-response relationship with the largest decreases in mortality observed among patients receiving at least 2 years' worth of prescriptions.
| Strengths and weaknesses
This is the first study to investigate ARB use and survival from gastro-oesophageal cancer. Our study is based on a high-quality population-based cohort of patients with registry-confirmed gastrooesophageal cancer which was followed up for up to 17 years. 29 Linkage to Office for National Statistics death registration data allowed robust verification of death, and facilitated a gastro-oesophageal cancer-specific analysis, which should be more sensitive to small changes in disease-specific mortality, and less susceptible to confounding by indication than all-cause deaths. 33, 42 Although some misclassification of death cause is possible, studies have shown this
T A B L E 1 Patient characteristics by ARB use

Non-user User
Number of patients 4764 360
Year of diagnosis (%) Adjusted for age, deprivation, year of diagnosis, cancer site, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease) and other medication use (statins and aspirin, time-varying after diagnosis).
is likely to have a limited impact on our estimates (as there is no obvious mechanism for differential misclassification), 43 and our results were similar when including deaths where gastro-oesophageal cancer was not the underlying cause. We used prescribing data collected as part of routine clinical care which accurately reflects GP prescribing practices and negates the risk of recall bias. These data also included detailed information on the type of ARB, and the strength, quantity and timing of prescription, which allowed us to investigate dose-response relationships, and conduct separate analyses for specific medications. ARBs are not available over-thecounter in the UK, which negates exposure misclassification due to over-the-counter usage.
Our study had several potential weaknesses. We necessarily excluded patients who lived for less than 6 months after diagnosis, therefore our results cannot be applied to those with a very poor prognosis. Our study is observational and hence open to confounding by incomplete or unmeasured covariates. Although we have adjusted for several key determinants of gastro-oesophageal cancer survival (e.g. age, comorbidities and cancer treatments), some were incompletely recorded (e.g. smoking history) and others were not available within our dataset (e.g. ethnicity and family history). The lack of complete information on cancer stage is of particular concern, especially as ARB users were more frequently diagnosed with lower-stage cancers than non-users (e.g. 16.9% vs 9.4% stage 1). It is also possible that our study could be subject to a "healthy user effect" whereby patients who receive one preventative therapy (ARBs) are more likely to use other therapies (e.g. endoscopy), or more closely follow medical advice (e.g. attend medical appointments). 44 Nevertheless, the findings from our sensitivity analyses suggest that confounding or missing data issues were not solely driving our results. For example, the protective association for ARBs was preserved when using other antihypertensive medications as an active comparator, when restricting to those who received surgery (who should form a more homogeneous cohort of lower-stage patients), and when limiting our analysis to patients with a prior hypertension diagnosis. Similarly, we observed little evidence of an association between gastro-oesophageal cancer mortality and ACE inhibitor use, which have similar indications to ARBs. Lastly, our conclusions were unchanged when using multiple imputation to adjust for cancer stage and grade, albeit this analysis is particularly sensitive to departures from the "missing at random" assumption due to the large proportion of missing data for these variables. 40 We do not know if patients adhered to their prescribed medications, however our main conclusions were similar when restricting our analysis to patients who received multiple ARB prescriptions (≥730 DDDs), where noncompliance is less of a concern. Finally, ARBs were one of six medications investigated within a broader programme of work, meaning that multiple testing could be a potential concern.
| Comparison with the previous literature
We are unaware of any other studies comparing gastro-oesophageal cancer mortality between ARB users and non-users. Several studies have previously investigated the role of renin-angiotensin system blockade on cancer survival. However they have generally combined ACE inhibitors with ARBs, 27 potentially obfuscating the therapeutic effect of each medication as they have distinct mechanisms of action within the renin-angiotensin system, and are known to differ in their side effect profiles. Our finding of a much stronger association with gastro-oesophageal survival among ARB than ACE inhibitor users could suggest that separate analyses are indeed preferable.
Nevertheless, our results are consistent with findings of longer survival among gastro-oesophageal cancer patients using reninangiotensin system blockade medications in two other studies based in Taiwan and Korea. 45, 46 However, each of these were substantially limited by poor generalisability (e.g. restricted to advanced gastric cancer), an inability to identify cancer-specific deaths, inappropriate statistical methods (e.g. chi-squared test) and small sample size (196 patients in total). Our study improves on the current literature by using appropriate methodology to analyse a population-based cohort over 30 times larger than previous work. Our results are also consistent with the findings from several other observational studies reporting improved survival among renin-angiotensin system blockade medication users at other sites. 26, 27 For example, one recent meta-analysis found that mortality was 25% (95% CI 1-43) lower among cancer patients using ACE inhibitors or ARBs, with particularly large decreases in urinary tract, colorectal, pancreatic and prostate cancer. 27 
| Implications for practitioners and researchers
Our results provide epidemiological evidence that the use of ARBs may be associated with improved gastro-oesophageal cancer survival. Our conclusions are consistent with preclinical research which has demonstrated that ARBs can slow tumour growth, stimulate cell apoptosis, reduce metastasis, and inhibit angiogenesis. [14] [15] [16] [17] [18] More specifically, ARBs have been shown to slow proliferation, inhibit fibrosis, and prevent stress-induced injury in gastric cancer cell line and animal model studies. [19] [20] [21] [22] [23] Our finding of a slightly stronger association among gastric than oesophageal cancer patients requires further exploration, however it could be due to higher renin-angiotensin system expression among patients with Helicobacter pylori infection, 47 the most important risk factor for gastric cancer. Likewise our finding of a slightly stronger association for adenocarcinoma than squamous cell carcinoma could be due to ARBs promoting healing of reflux oesophagitis among proton pump inhibitor users. 48 Our study suggests that it is worth further exploring the potential for ARBs to be repurposed as a gastro-oesophageal cancer treatment, particularly as they are inexpensive (losartan costs £1.15
[$1.48] per 28-tablet pack), 49 have no major safety concerns, 50 and are well tolerated by patients. 51 In this article, we have demonstrated that the association with gastro-oesophageal cancer mortality adheres to several of Hill's criteria for causation including biological plausibility, experimental evidence, temporality, biological gradient, consistency and specificity. 52 However, these findings should be replicated in independent epidemiological studies with more complete information on cancer stage.
| CONCLUSION S
In this large population-based cohort of patients with registry-confirmed gastro-oesophageal cancer, we found a 17% reduction in cancer-specific mortality among ARB users. Although this association adheres to several of Hill's criteria for causation, and is consistent with preclinical evidence, further independent epidemiological studies with more complete stage data are required.
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